öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

ФÑÜÓŮ£¬Öй²²úµ³Ô±£¬²©Ê¿£¬Ò©¼ÁѧöλÔÓéÀֵǼÈë¿ÚÏÂÔظ±½ÌÊÚ£¬Ë¶Ê¿Ñо¿Éúµ¼Ê¦£¬ÏÖÈÎÖйúÒ©¿Æ´óѧҩѧԺҩ¼Á½ÌÑÐÊÒ½Ìʦ£¬¹ú¼Ò·¢¸ÄίҩƷ¼Û¸ñÆÀÉóר¼Ò¡£Ä¿Ç°µÄÑо¿·½ÏòΪÐÂÖƼÁÓëм¼ÊõÑо¿¡£

ÁªÏµ·½Ê½£ºcpuyanyuxiao@163.com

ÁªÏµµç»°£º13813954610

1¡¢Ñ§Ï°¡¢¹¤×÷¾­Àú

1996.9-2000.6ÖйúÒ©¿Æ´óѧҩ¼ÁöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¨±¾¿Æ£©
2002.9-2007.6ÖйúÒ©¿Æ´óѧҩ¼ÁѧöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£¨²©Ê¿£¬Ë¶²©Á¬¶Á£¬µ¼Ê¦£ºÆ½ÆäÄܽÌÊÚ£©
2000.7-2002.8½­Î÷ÖÐҽѧԺҩ¼Á½ÌÑÐÊÒÖú½Ì
2007.7-2010.4ÖйúÒ©¿Æ´óѧ½²Ê¦
2010.5-2011.7ÖйúÒ©¿Æ´óѧ¸±½ÌÊÚ
2011.7-ÖÁ½ñÖйúÒ©¿Æ´óѧ¸±½ÌÊÚ˶ʿÑо¿Éúµ¼Ê¦
2014.6-2015.6£¬ÃÀ¹úÔ¼º²»ôÆÕ½ð˹ҽѧԺ£¬·ÃÎÊѧÕß

2¡¢½Ìѧ·½Ãæ

Ö÷½²±¾¿ÆÉú¿Î³Ì¡¶Ò©¼Áѧ¡·ºÍ¡¶Ò©ÎïÖƼÁ¹¤³Ìѧ¡·¡£Ö÷³Ö“ÖйúÒ©¿Æ´óѧУ¼¶½Ìѧ¸Ä¸ï¿ÎÌâ”1Ïî¡£»ñÖйúÒ©¿Æ´óѧҩѧԺµÚËĽìÇàÄê½Ìʦ½²¿Î±ÈÈüÈýµÈ½±£¨2009Ä꣩¡¢»ñ¹ú¼ÊÌØÆ·¹«Ë¾£¨ISP£©½±½Ì½ð£¨2011Ä꣩¡¢»ñ2012¡¢2013Äê¶È“¹ú¼Ò¼¶´óѧÉú´´Ð´´ÒµÑµÁ·¼Æ»®ÏîÄ¿-Ö¸µ¼½Ìʦ”ÈÙÓþ³ÆºÅ¡¢»ñ“ÖйúÒ©¿Æ´óѧ2012¼¶±¾¿ÆÉúµ¼Ê¦”ÈÙÓþ³ÆºÅ¡£

3¡¢¿ÆÑз½Ãæ

Ö÷³Ö¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÇàÄê»ù½ðÏîÄ¿¡¢½­ËÕÊ¡×ÔÈ»¿Æѧ»ù½ðÇàÄêÏîÄ¿¡¢ÖÐÑë¸ßУ»ù±¾¿ÆÑÐÒµÎñ·ÑרÏî×ʽðÇàÄêÏîÄ¿¡¢ÖÐÑë¸ßУ»ù±¾¿ÆÑÐÒµÎñ·ÑרÏî×ʽðÅàÓýÏîÄ¿¡¢ÖйúÒ©¿Æ´óѧÒý½øÈ˲ÅÆô¶¯×ʽðÏîÄ¿¸÷1Ï²ÎÓëÍê³ÉʮһÎå¹ú¼Ò¿Æ¼¼ÖØ´óרÏî¼°¶àÏî¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÏîÄ¿¡£Í¬Ê±£¬Ö÷³Ö»ò²ÎÓë¶àÏîºáÏò¿ª·¢ÏîÄ¿ºÍ²úҵת»¯¹¤×÷µÈ£¬²¢ÓëÆóÒµºÏ×÷³ÉÁ¢Ò»¸öУÆóÁªºÏʵÑéÊÒ¡£
»ñ½­ËÕÊ¡¿Æ¼¼½ø²½¶þµÈ½±£¨2009Ä꣩¡¢»ñµÃºÓÄÏÊ¡Ò½Ò©ÎÀÉú¿Æ¼¼³É¹û¶þµÈ½±£¨2009Ä꣩¡¢Æù½ñ·¢±íÂÛÎÄ71ƪ£¬ÆäÖÐSCIÊÕÔØ21ƪ£»²Î±à¡¶ÖÐÒ©³É·ÖµÄθ³¦×ªÔËÓë¼ÁÐÍÉè¼Æ¡·¼°¡¶Ò©ÎïÉúÎïÒ©¼ÁѧÐÅÏ¢Êý¾Ý¿â¡·Èí¼þµÄ¿ª·¢£¬2010ÄêÕýʽ³ö°æ¡£²Î±àÖø×÷¡¶Ò©¼Áѧ¡·£¨ÈËÃñÎÀÉú³ö°æÉ磩£¬2013ÄêÕýʽ³ö°æ¡£ÉêÇëרÀû13ÏÊÚȨ8Ïî¡£

4¡¢´ú±íÐÔÎÄÕ£º
1.Meng F, Asghar S, Gao S, Su Z, Song J, Huo M, Meng W, Ping Q, Xiao Y*. A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer's disease. Colloids Surf B Biointerfaces. 2015, 134:88-97.
2.Gao S, Xu Y, Asghar S, Chen M, Zou L, Eltayeb S, Huo M, Ping Q, Xiao Y*, Polybutylcyanoacrylate nanocarriers as promising targeted drug delivery systems. J Drug Target. 2015, 23(6):481-96.
3.Yang L, Gao S, Asghar S, Liu G, Song J, Wang X, Ping Q, Zhang C, Xiao Y*, Hyaluronic acid/chitosan nanoparticles for delivery of curcuminoid and its in vitro evaluation in glioma cells. Int J Biol Macromol. 2015, 72:1391-401.
4.Su Z, Xing L, Chen Y, Xu Y, Yang F, Zhang C, Ping Q, Xiao Y*, Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas, Mol Pharm, 2014, 11(6):1823-34.
5. Xiao Y, Chen X, Yang L, Zhu X, Zou L, Meng F, Ping Q*, Preparation and oral bioavailability study of curcuminoid-loaded microemulsion, J Agric Food Chem, 2013, 61(15):3654-60
6.Yanyu X, Qineng P*, Zhigui S, Hongying L, Jiangxiu N, Preparation and pharmacokinetics in beagle dogs of once-a-day tetramethylpyrazine phosphate sustained-release pellets, Drug Dev Ind Pharm, 2012, 38(3), 301-306
7.Yanyu X, Fang L, Qineng P*, Hao C, The influence of the structure and the composition of water/AOT-Tween 85/IPM microemulsion system on transdermal delivery of 5-fluorouracil, Drug Dev Ind Pharm, 2012, 38(12), 1521-1529
8.Yanyu X, Qineng P, Zhipeng C. The enhancing effect of synthetical borneol on the absorption of tetramethylpyrazine phosphate in mouse. Int J Pharm, 2007, 337(1-2):74-79
9.Yanyu X, Yunmei S, Zhipeng C, Qineng P. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. Int J Pharm. 2006, 319(1-2):162 -168